Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.64), $0.14 better than the analyst estimate of ($0.78).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Equirus Starts JSW Energy Ltd (JSW:IN) at Long (1)
• Morgan Stanley more than doubles Lenovo price target on AI-driven growth